Corline Biomedical AB (CLBIO.ST)
SEK 8.76
(5.29%)
SEK 8.76
(5.29%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 25.03 Million SEK | 6.28% |
| 2022 | 23.55 Million SEK | 233.47% |
| 2021 | 7.06 Million SEK | 91.07% |
| 2020 | 3.69 Million SEK | 247.37% |
| 2019 | 1.06 Million SEK | -31.93% |
| 2018 | 1.56 Million SEK | 144.98% |
| 2017 | 638 Thousand SEK | -32.63% |
| 2016 | 947 Thousand SEK | -8.69% |
| 2015 | 1.03 Million SEK | -38.39% |
| 2014 | 1.68 Million SEK | -5.84% |
| 2013 | 1.78 Million SEK | -70.2% |
| 2012 | 5.99 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.25 Million SEK | -39.67% |
| 2024 Q1 | 3.73 Million SEK | -40.13% |
| 2023 Q2 | 6.07 Million SEK | -17.84% |
| 2023 Q1 | 7.39 Million SEK | -10.27% |
| 2023 FY | 25.03 Million SEK | 6.28% |
| 2023 Q3 | 5.31 Million SEK | -12.64% |
| 2023 Q4 | 6.24 Million SEK | 17.59% |
| 2022 Q4 | 8.24 Million SEK | 17.32% |
| 2022 FY | 23.55 Million SEK | 233.47% |
| 2022 Q3 | 7.02 Million SEK | 34.97% |
| 2022 Q2 | 5.2 Million SEK | 69.61% |
| 2022 Q1 | 3.07 Million SEK | -5.25% |
| 2021 Q1 | 1.53 Million SEK | -39.51% |
| 2021 Q4 | 3.24 Million SEK | 236.8% |
| 2021 Q2 | 1.32 Million SEK | -13.56% |
| 2021 Q3 | 962 Thousand SEK | -27.45% |
| 2021 FY | 7.06 Million SEK | 91.07% |
| 2020 Q1 | 191 Thousand SEK | -54.2% |
| 2020 Q3 | 368 Thousand SEK | -38.77% |
| 2020 Q4 | 2.53 Million SEK | 589.13% |
| 2020 FY | 3.69 Million SEK | 247.37% |
| 2020 Q2 | 601 Thousand SEK | 214.66% |
| 2019 Q2 | 369 Thousand SEK | 163.57% |
| 2019 Q1 | 140 Thousand SEK | -74.31% |
| 2019 Q3 | 138 Thousand SEK | -62.6% |
| 2019 FY | 1.06 Million SEK | -31.93% |
| 2019 Q4 | 417 Thousand SEK | 202.17% |
| 2018 FY | 1.56 Million SEK | 144.98% |
| 2018 Q4 | 545 Thousand SEK | 50.55% |
| 2018 Q1 | 310 Thousand SEK | 58.16% |
| 2018 Q3 | 362 Thousand SEK | 4.62% |
| 2018 Q2 | 346 Thousand SEK | 11.61% |
| 2017 FY | 638 Thousand SEK | -32.63% |
| 2017 Q2 | 103 Thousand SEK | -52.53% |
| 2017 Q3 | 122 Thousand SEK | 18.45% |
| 2017 Q4 | 196 Thousand SEK | 60.66% |
| 2017 Q1 | 217 Thousand SEK | 5.34% |
| 2016 Q2 | 367 Thousand SEK | 68.61% |
| 2016 FY | 947 Thousand SEK | -8.69% |
| 2016 Q1 | 217.66 Thousand SEK | 45.24% |
| 2016 Q4 | 206 Thousand SEK | 30.38% |
| 2016 Q3 | 158 Thousand SEK | -56.95% |
| 2015 Q4 | 149.86 Thousand SEK | -35.28% |
| 2015 FY | 1.03 Million SEK | -38.39% |
| 2015 Q1 | 112.23 Thousand SEK | -83.43% |
| 2015 Q2 | 543.43 Thousand SEK | 384.2% |
| 2015 Q3 | 231.55 Thousand SEK | -57.39% |
| 2014 Q3 | 260.18 Thousand SEK | -47.34% |
| 2014 Q4 | 677.15 Thousand SEK | 160.26% |
| 2014 FY | 1.68 Million SEK | -5.84% |
| 2014 Q2 | 494.05 Thousand SEK | 0.0% |
| 2013 FY | 1.78 Million SEK | -70.2% |
| 2012 FY | 5.99 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 56.924% |
| Ziccum AB (publ) | 3.74 Million SEK | -568.001% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 95.937% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 50.421% |
| Mendus AB (publ) | 28.48 Million SEK | 12.135% |
| Genovis AB (publ.) | 158.23 Million SEK | 84.181% |
| Intervacc AB (publ) | 8.01 Million SEK | -212.289% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -472.245% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 85.314% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 42.979% |
| Aptahem AB (publ) | 2.63 Million SEK | -851.477% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -2318.357% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -32406.494% |
| Fluicell AB (publ) | 3.33 Million SEK | -649.85% |
| Saniona AB (publ) | 16.84 Million SEK | -48.634% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -52.557% |
| Biovica International AB (publ) | 7.29 Million SEK | -243.347% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -1980.632% |
| AcouSort AB (publ) | 10.55 Million SEK | -137.229% |
| Xintela AB (publ) | 78 Thousand SEK | -31989.744% |
| Abliva AB (publ) | 137 Thousand SEK | -18170.073% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 56.545% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -1142.8% |
| OncoZenge AB (publ) | 3000.00 SEK | -834233.333% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -16048.387% |
| CombiGene AB (publ) | 5.54 Million SEK | -351.47% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 97.926% |
| Camurus AB (publ) | 1.71 Billion SEK | 98.542% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -340.824% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -3371.567% |
| I-Tech AB | 120.86 Million SEK | 79.29% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 81.334% |
| Cyxone AB (publ) | 5.14 Million SEK | -386.208% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -255.035% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -134.7% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -122.884% |
| Nanologica AB (publ) | 1.44 Million SEK | -1634.581% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -47126.415% |
| BioInvent International AB (publ) | 71.46 Million SEK | 64.974% |
| Alzinova AB (publ) | 270 Thousand SEK | -9170.37% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 28.932% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -1610.845% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -786.96% |
| Simris Alg AB (publ) | 4.35 Million SEK | -474.874% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -19153.846% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 89.515% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -108726.087% |